---
layout: post
title: "Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability"
date: 2026-02-05 18:55:06 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-07243
original_published: 2023-04-06 00:00:00 +0000
significance: 8.00
---

# Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** April 06, 2023 00:00 UTC
**Document Number:** 2023-07243

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Patient- Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making." This draft guidance (Guidance 4) is the fourth in a series of four methodological patient- focused drug development (PFDD) guidance documents that describe how stakeholders (patients, researchers, medical product developers, and others) can collect and submit patient experience data and other relevant information from patients and caregivers to be used for medical product development and regulatory decision-making.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/04/06/2023-07243/patient-focused-drug-development-incorporating-clinical-outcome-assessments-into-endpoints-for)
- API: https://www.federalregister.gov/api/v1/documents/2023-07243

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
